quarta-feira, 21 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· January 8, 2026

Croissance organique de +6,0 % au premier trimestre 2026 - Confirmation des objectifs annuels

View original at globenewswire.com
Croissance organique de +6,0 % au premier trimestre 2026 - Confirmation des objectifs annuels Communiqué de presse Roubaix, 8 janvier 2026 Croissance organique de +6,0 % au premier trimestre 2026 Confirmation des objectifs annuels Chiffre d’affaires par segment de produits (en millions d'euros)2025 1er trimestre2026 1e…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Company is structured toward new target of €2 billion revenue

    80% confidence

  • Net revenue retention rate reached 105% on a comparable basis

    80% confidence

  • Q1 revenue exceeded €275 million with 6.0% organic growth

    80% confidence

  • OVHcloud confirms all FY2026 objectives including positive Free Cash-Flow generation

    80% confidence

  • Supply chain optimization initiated in 2025 allows continued service delivery while respecting investment envelope

    80% confidence

  • Group maintained operational and financial discipline, particularly on general and administrative expense control

    80% confidence

Citado nestas reportagens da Via News

O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Q4 2026 Biopharma Catalyst Crunch: Late-Stage Readouts and Regulatory Milestones Converge on the Ivonescimab PDUFA Date
October 2026 is dense with clinical and regulatory news. Phase 3 trials hit primary endpoints (ALOFT-IPF, RESTORE-3), long-term data came out (MIUDELLA at 6 years, QUILT-3.032), and the FDA accepted Roche's vamikibart BLA. Scholar Rock resubmitted its apitegromab MAA to the EMA. The next catalysts are ESMO 2026 (Oct 23) and the Nov 14 FDA PDUFA date for ivonescimab, followed by Maritime-1 primary completion in January 2027. The speculative QAIAx items (QIII pilot, microcities patent) are a weak, tangential thread with little financial substance.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,406 documentos-fonte arquivados
Consulte estes dados → isubstrate.com